secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0001193125-23-214362
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics prices $70M underwritten offering of 7.8M shares at $9.00
--------------------------------------------------------------------------

- Underwritten offering of 7,777,778 shares at $9.00/share, gross proceeds ~$70M.
- Investors include RA Capital, TCGX, Frazier Life Sciences, Marshall Wace, Adage Capital, Avidity Partners, Janus Henderson, Surveyor Capital.
- Expected close on Aug 18, 2023; Cowen, Leerink, Evercore as book-runners.
- Offering priced at premium to closing price; sold under effective shelf registration statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312523214362/0001193125-23-214362-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312523214362/d510715d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-214362

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer